Reduced hippocampal metabolism in MCI and AD: Automated FDG-PET image analysis

Neurology

Volumn 64, Issue 11, 2005, Pages 1860-1867

  Mosconi, L ^a,c   Tsui, W H ^a,b   De Santi, S ^a   Li, J ^a   Rusinek, H ^a   Convit, A ^a,b   Li, Y ^a   Boppana, Madhu ^a   De Leon, Mony J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOMATION; BRAIN CORTEX; BRAIN METABOLISM; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; ELECTROENCEPHALOGRAM; FEMALE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; COHORT STUDIES; DOWN-REGULATION; ENERGY METABOLISM; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SOFTWARE DESIGN;

EID: 20444423242     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000163856.13524.08     Document Type: Article

References (50)

1. de Leon MJ, Ferris SH, George A, et al. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab 1983;3:276-394.
2. Foster NL, Chase TN, Mansi L, et al. Cortical abnormalities in Alzheimer's disease. Ann Neurol 1984;16:649-654.
3. Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlations in Alzheimer's disease. Lancet 1985;26:228.
4. Koss E, Friedland RP, Ober BA, Jagust WJ. Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia. Am J Psychiatry 1985;142:638-640.
5. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
6. Ouchi Y, Nobezawa S, Okada H, Yoshikawa E, Futatsubashi M, Kaneko M. Altered glucose metabolism in the hippocampal head in memory impairment. Neurology 1998;51:136-142.
7. de Leon MJ, McRae T, Rusinek H, et al. Cortisol reduces hippocampal glucose metabolism in normal elderly but not in Alzheimer's disease. J Clin Endocrinol Metab 1997;82:3251-3259.
8. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966-10971.
9. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-539.
10. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003;54:343-351.
11. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991;11:690-699.
12. Friston K, Ashburner J, Frith C, Poline J-B, Heather J, Frackowiak R. Spatial registration and normalization of images. Hum Brain Mapp 1995;3:165-189.
13. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of Fluorine-18-FDG PET. J Nucl Med 1995;36:1238-1248.
14. Folstein M. The Mini-Mental State Examination. In: Crook T, Ferris SH, Bartus R, eds. Assessment in geriatric psychopharmacology. New Canaan: Mark Powley Associates, 1983;47-51.
15. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health & Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (fourth edition). Washington, DC: American Psychiatric Association, 1994.
18. Tsui WH, Rusinek H, Van Gelder P, Lebedev S. Analyzing multimodality tomographic images and associated regions of interest with MIDAS. Proc SPIE Med Imaging: Image Processing 2001;4322:1725-1734.
19. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
20. Reivich M, Alavi A, Wolf A, et al. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab 1985;5:179-192.
21. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17:536-546.
22. Good CD, Scahill RI, Fox NC, et al. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage 2002;17:29-46.
23. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. Stuttgart: Thieme, 1988.
24. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
25. Agresti A. An introduction to categorical data analysis. New York: Wiley, 1996.
26. Meltzer CC, Bryan NR, Holcomb HH, et al. Anatomical localization for PET using MRI imaging. J Comput Assist Tomogr 1990;14:418-426.
27. Ibanez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1999;50:1585-1593.
28. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer's disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995;19:541-547.
29. Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995;2:189-210.
30. Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-1377.
31. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-1113.
32. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332-2340.
33. de Leon MJ, Smith G, Convit A, et al. The early detection of brain pathology in Alzheimer's disease. In: Christen Y, Churchland P, eds. Neurophysiology in Alzheimer's disease. New York: Springer-Verlag, 1992;131-143.
34. Gomez-Isla T, Price JL, McKeel DW, Jr., Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996;16:4491-4500.
35. Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999;52:1158-1165.
36. Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet 2004;348:94-97.
37. Jagust WJ, Eberling JL, Richardson BC, et al. The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease. Brain Res 1993;629:189-198.
38. McKelvey R, Bergman H, Stern J, Rush C, Zahirney G, Chertkow H. Lack of prognostic significance of SPECT abnormalities in non-demented elderly subjects with memory loss. Can J Neurol Sci 1999;26:23-28.
39. Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E. Relatively preserved hippocampal glucose metabolism in mild Alzheimer's disease. Dement Geriatr Cogn Dis 1998;9:317-322.
40. Chetelat G, Desgranges B, De La Sayette V, et al. Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 2003;126:1955-1967.
41. Reed BR, Jagust WJ, Seab JP, Ober BA. Memory and regional cerebral blood flow in mildly symptomatic Alzheimer's disease. Neurology 1989;39:1537-1539.
42. Powers WJ, Perlmutter JS, Videen TO, et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease. Neurology 1992;42:765-770.
43. Small GW, Okonek A, Mandelkern MA, et al. Age-associated memory loss: initial neuropsychological and cerebral metabolic findings of a longitudinal study. Int Psychogeriatr 1994;6:23-44.
44. Jagust WJ. Functional imaging in dementia: an overview. J Clin Psychiatry 1994;55 suppl:5-11.
45. Hoffman JM, Guze BH, Baxter LR, Mazziotta JC, Phelps ME. [18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET) in aging and dementia. A decade of studies. Eur Neurology 1989;29(suppl 3):16-24.
46. Gilley DW, Wilson RS, Bennet DA, Bernard BA, Fox JH. Predictors of behavioral disturbance in Alzheimer's disease. J Gerontol: Psych Sci 1991;46:362-371.
47. Berent S, Giordani B, Foster N, et al. Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J Psychiatr Res 1999;33:7-16.
48. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
49. Silverman DHS, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-2127.
50. Silverman DHS, Truong CT, Kim SK, et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab 2003;80:350-355.